Aptus Pharma H2 FY26: 118% Sales Growth, 30% ROE, But Negative Cash Flow Raises the Real Question
1. At a Glance – A Pharma Distributor Acting Like a Growth Stock
Sometimes small companies scream “multibagger” so loudly that investors stop reading the balance sheet.
That is usually when trouble begins.
Aptus Pharma Ltd has come with exactly the sort of numbers that excite the market. Revenue jumped from ₹24.56 crore to ₹46.57 crore in FY26. PAT rose from ₹3.10 crore to ₹4.62 crore. Three-year profit growth sits at 190%. ROE is above 30%. ROCE near 30%. And then management casually announces a 3:2 bonus issue.
Classic market seduction.
The stock trades at 57.7 times earnings. For a contract-manufactured pharma distributor.
That deserves scrutiny.
Because beneath the growth story sits a fascinating contradiction:
Profits rising fast
Cash flow deteriorating
Receivables ballooning
Inventory heavy
Debtor days exploding from 84 to 147 days
Free cash flow deeply negative
This is where investing stops being arithmetic and becomes detective work.
And this company invites detective work.
On one hand, you have an asset-light marketer using outsourced manufacturing, which can be a beautiful model when scale comes. Think less factory risk, more brand leverage.
On the other hand, the working capital cycle looks like a patient with high cholesterol pretending to run marathons.
That does not make the business broken.
It makes it interesting.
IPO funds of ₹13.02 crore (₹1,302 lakhs) have reportedly been fully utilised. Management has pushed expansion, product pipeline, exports ambitions, new state entry, even 450+ products vision by 2030.
Ambition is not lacking.
But can management convert ambition into cash?
That is the whole story.
Because sometimes small pharma companies do not fail from lack of demand.
They fail because growth eats cash faster than profits can replenish it.
And that is exactly the tension here.
Question for readers:
Is this a fast-scaling branded pharma play in early innings…
Or a working capital machine dressed as a growth story?
That question matters far more than the bonus issue headlines.
2. Introduction — A Tiny Pharma With Big Market Ambitions
This is not a manufacturer.
That matters.
Aptus is effectively a branded formulation marketer sitting on top of outsourced manufacturing partners. Seven manufacturing partners, 194 products, 11 therapy segments, mostly Gujarat concentrated business.
This is a distribution-intelligence business.
And sometimes those are underrated.
Why?
Because they can scale faster than manufacturers.
No capex burden. No plant headaches. No USFDA horror stories. No “import alert destroyed valuation overnight” drama.
Very convenient.
But then you notice Gujarat contributes 99%+ of revenue.
And you realize pan-India dreams remain… dreams.
Still, there is genuine operating momentum.
Revenue nearly doubled.
Quarterly sales up 118%.
Quarterly PAT up 60%.
Few SMEs show those numbers.
But markets are paying for that already.
P/E of 57.7 versus sector median 30.6 is not cheap optimism.
That is premium optimism.
Premium optimism must be earned.
Can they?
Let’s inspect.
3. Business Model — What Do They Even Do?
Think of Aptus as a pharma brand-builder without factories.
It identifies products.
Gets third parties to manufacture.
Runs branding.
Pushes through distributors and doctors.
Collects margins.
Very simple.
Very scalable.
Very dependent on execution.
Segments include:
Anti infectives (29.4%)
Respiratory/allergy
GI
Pain
Cardio diabetic
Nutraceuticals
Pioneer division contributes 95% revenue.
That concentration is both strength and red flag.
If one division sneezes…
everyone catches cold.
The model can work wonderfully.
But contract manufacturing businesses often fool investors into confusing “asset light” with “risk light.”
Not same thing.
Asset light can mean outsourced risk.
Question:
If manufacturers hold quality risk and working capital keeps expanding — who really controls the economics?
